Uppsala, Sweden

Hillevi Englund



 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2011-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hillevi Englund: Innovator in Neurodegenerative Disease Research

Introduction

Hillevi Englund is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of neurodegenerative diseases, particularly Alzheimer's disease. With a total of two patents to her name, her work focuses on innovative therapeutic approaches.

Latest Patents

Englund's latest patents include "Protofibril selective antibodies and the use thereof." This invention relates to an isolated antibody, or fragment thereof, that has a high affinity for human Aβ protofibrils. The invention further encompasses compositions that include the antibody or a fragment thereof, along with a pharmaceutically acceptable buffer. Additionally, it outlines a method for preventing or treating Alzheimer's disease by administering such an antibody or composition to patients. Another patent under her name also pertains to the prevention, treatment, and diagnosis of neurodegenerative diseases, specifically targeting high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation.

Career Highlights

Hillevi Englund has worked with notable companies in the field, including Bioarctic Neuroscience AB. Her research has been pivotal in advancing the understanding and treatment of Alzheimer's disease.

Collaborations

Englund has collaborated with esteemed colleagues such as Pär Gellerfors and Lars Lannfelt, contributing to the collective effort in neurodegenerative disease research.

Conclusion

Hillevi Englund's innovative work and patents in the field of Alzheimer's disease highlight her as a key figure in neurodegenerative research. Her contributions continue to pave the way for potential treatments and advancements in understanding these complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…